Johnson & Johnson

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-06-20 pm EDT			After hours 04:21:36 pm
149.79 ^USD	-0.62%		150.02	+0.16%

12:35pm	Johnson & Johnson Unit Receives Positive EU Opinion for Imbruvica Indication Extension	MT
12:11pm	Janssen-Cilag Gets EU Panel Backing for New Indication for Darzalex	MT

Top Midday Decliners

Published on 04/01/2025 at 14:31, updated on 04/01/2025 at 14:32

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Johnson & Johnson

Johnson & Johnson Unit Receives Positive EU Opinion for Imbruvica Indication Extension	12:35pm	MT
Janssen-Cilag Gets EU Panel Backing for New Indication for Darzalex	12:11pm	MT
J&J: CMHP green light for Darzalex SC in myeloma	10:06am	CF
J&J: CHMP gives positive opinion for Imbruvica in lymphoma	09:48am	CF
J&J Launches Volt Wrist And Proximal Humerus Plating Systems In US	Jun. 19	RE
J&J: launches two VOLT plate systems	Jun. 19	CF
AbbVie's migraine drug meets main goal of late-stage study	Jun. 18	RE
Top Midday Stories: Shares Decline Amid Unease Over Israel-Iran Conflict; Retail Sales Fall More Than Expected in May	Jun. 17	MT
Trump Administration to Consider Pharma Advertising Crackdown	Jun. 17	MT
Trump Administration to Consider Pharma Advertising Crackdown, Bloomberg reports	Jun. 17	MT
Johnson & Johnson, Q1 2025 Earnings Call, Apr 15, 2025	Jun. 17
J&J: launches TECNIS Odyssey intraocular lens	Jun. 17	CF
Johnson & Johnson Says Drug Combo Study Shows 'Deep, Durable' Responses Multiple Myeloma Patients With Extramedullary Disease	Jun. 16	MT
Johnson & Johnson Says Talvey,Tecvayli Shows Deep,Durable Responses In Heavily Pretreated Multiple Myeloma Patients With Extramedullary Disease	Jun. 15	RE
Johnson & Johnson Announces New Results from the Phase 2 RedirecTT-1 Study Evaluating the Investigational Combination of TALVEY®?	Jun. 15	CI
Sector Update: Health Care Stocks Softer Friday Afternoon	Jun. 13	MT
Johnson & Johnson's Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Results in Large B-Cell Lymphoma	Jun. 13	CI
Johnson & Johnson T-Cell Therapy Shows Promising Initial Results in Lymphoma Study	Jun. 13	DJ
Johnson & Johnson Says Therapy Shows 'Encouraging' First Trial Results in Large B-cell Lymphoma	Jun. 13	MT
Kenvue mulls sale of some skin health and beauty brands, sources say	Jun. 12	RE
New Results for Johnson & Johnson's Bleximenib Demonstrating Antileukemic Activity in Combination with Venetoclax and Azacitidine for Acute Myeloid Leukemia	Jun. 12	CI
US Senators Introduce Bill to Ban Direct-to-Consumer Drug Ads	Jun. 12	MT
Johnson & Johnson Says Phase 1b Trial Shows Promise for Bleximenib Combo in AML Treatment	Jun. 12	MT
J&J: Imbruvica shows promise in lymphocytic leukemia	Jun. 12	CF
Significant Efficacy Benefit Of IMBRUVICA Plus Venetoclax Versus Acalabrutinib Plus Venetoclax In Frontline Treatment Of Patients With Chronic Lymphocytic Leukaemia Suggested By Indirect Treatment Comparison	Jun. 12	RE

Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (64.1%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (35.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; At the end of 2024, Johnson & Johnson has 64 manufacturing facilities located in the United States (23), North America (7), Europe (21), Africa and Asia/Pacific (13). The United States accounts for 56.6% of net sales.

Employees

138,100

Sector

Pharmaceuticals

Calendar

Jul. 16 - Q2 2025 Earnings Release

More about the company